Loading...
[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
BACKGROUND: Angiogenesis is a driver of platinum resistance in ovarian cancer. We assessed the effect of combination pazopanib and paclitaxel followed by maintenance pazopanib in patients with platinum-resistant/refractory ovarian cancer. Integrins α(v)β(3) and α(v)β(5) are both upregulated in tumor...
Na minha lista:
| Udgivet i: | Eur J Nucl Med Mol Imaging |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7101300/ https://ncbi.nlm.nih.gov/pubmed/31754793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04532-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|